Latest Ratios: P/E Ratio -95.3x · EV/EBITDA 17.8x · ROE -4.3%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13.4B | $10.1B | $9.6B | $12.2B | $11.2B | $19.4B | $12.6B | $7.6B | $5.5B | $5.3B | $3.7B |
| Enterprise Value | $16.2B | $12.9B | $12.1B | $15.0B | $14.0B | $22.3B | $14.6B | $9.4B | $7.0B | $6.3B | $4.8B |
| P/E Ratio → | -95.30 | — | 930.80 | 25.64 | 22.99 | 49.58 | 34.70 | 30.13 | 24.50 | 43.09 | 23.59 |
| P/S Ratio | 3.33 | 2.51 | 2.37 | 2.95 | 2.81 | 5.47 | 4.32 | 2.90 | 2.45 | 2.86 | 2.17 |
| P/B Ratio | 4.28 | 3.14 | 2.74 | 3.32 | 3.70 | 7.48 | 5.90 | 4.56 | 4.15 | 5.00 | 4.28 |
| P/FCF | 25.76 | 19.47 | 19.16 | 33.29 | 37.91 | 36.42 | 33.28 | 22.30 | 18.43 | 22.73 | 15.03 |
| P/OCF | 18.11 | 13.68 | 13.08 | 17.78 | 18.04 | 25.47 | 23.14 | 15.78 | 12.58 | 16.81 | 12.25 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.22 | 3.00 | 3.62 | 3.53 | 6.31 | 4.99 | 3.58 | 3.11 | 3.39 | 2.84 |
| EV / EBITDA | 17.79 | 14.21 | 20.61 | 16.05 | 14.71 | 26.12 | 21.83 | 17.07 | 14.29 | 15.01 | 13.10 |
| EV / EBIT | 31.92 | 1720.16 | 55.33 | 20.83 | 20.58 | 40.28 | 27.32 | 25.70 | 20.41 | 19.27 | 19.04 |
| EV / FCF | — | 24.97 | 24.20 | 40.92 | 47.61 | 41.99 | 38.36 | 27.55 | 23.41 | 26.93 | 19.63 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.5% | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% | 36.6% | 37.1% | 37.7% | 38.3% |
| Operating Margin | 12.6% | 12.6% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% |
| Net Profit Margin | -3.6% | -3.6% | 0.3% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -4.3% | -4.3% | 0.3% | 14.2% | 17.3% | 16.5% | 19.1% | 16.8% | 18.8% | 12.9% | 19.1% |
| ROA | -2.0% | -2.0% | 0.1% | 6.0% | 6.6% | 6.2% | 7.2% | 5.9% | 6.7% | 4.4% | 6.5% |
| ROIC | 6.3% | 6.3% | 2.7% | 7.5% | 8.5% | 9.2% | 8.6% | 8.4% | 10.2% | 10.8% | 10.2% |
| ROCE | 8.1% | 8.1% | 3.3% | 9.0% | 10.4% | 11.1% | 10.0% | 9.6% | 11.5% | 12.1% | 11.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.95 | 0.95 | 0.78 | 0.84 | 1.02 | 1.24 | 1.01 | 1.22 | 1.27 | 1.08 | 1.45 |
| Debt / EBITDA | 3.36 | 3.36 | 4.62 | 3.29 | 3.24 | 3.75 | 3.24 | 3.69 | 3.44 | 2.73 | 3.39 |
| Net Debt / Equity | — | 0.89 | 0.72 | 0.76 | 0.95 | 1.14 | 0.90 | 1.07 | 1.12 | 0.92 | 1.31 |
| Net Debt / EBITDA | 3.13 | 3.13 | 4.29 | 3.00 | 3.00 | 3.47 | 2.89 | 3.25 | 3.05 | 2.34 | 3.07 |
| Debt / FCF | — | 5.50 | 5.04 | 7.64 | 9.71 | 5.57 | 5.08 | 5.25 | 4.99 | 4.20 | 4.60 |
| Interest Coverage | 0.07 | 0.07 | 1.74 | 5.25 | 11.51 | 7.50 | 6.17 | 5.99 | 5.42 | 10.97 | 9.05 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.29 | 1.29 | 1.41 | 1.52 | 1.32 | 1.23 | 1.43 | 1.44 | 1.61 | 1.78 | 1.53 |
| Quick Ratio | 1.02 | 1.02 | 1.13 | 1.16 | 1.08 | 1.04 | 1.21 | 1.21 | 1.38 | 1.54 | 1.31 |
| Cash Ratio | 0.19 | 0.19 | 0.20 | 0.26 | 0.21 | 0.24 | 0.27 | 0.34 | 0.35 | 0.35 | 0.27 |
| Asset Turnover | — | 0.56 | 0.54 | 0.50 | 0.52 | 0.50 | 0.53 | 0.56 | 0.59 | 0.63 | 0.62 |
| Inventory Turnover | 9.33 | 9.33 | 9.76 | 6.91 | 9.83 | 11.07 | 9.96 | 10.35 | 11.15 | 10.06 | 10.83 |
| Days Sales Outstanding | — | 64.44 | 64.97 | 68.98 | 69.07 | 67.06 | 77.11 | 71.58 | 76.06 | 84.49 | 79.03 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.1% | 3.9% | 4.4% | 2.0% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% |
| FCF Yield | 3.9% | 5.1% | 5.2% | 3.0% | 2.6% | 2.7% | 3.0% | 4.5% | 5.4% | 4.4% | 6.7% |
| Buyback Yield | 2.7% | 3.6% | 1.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 2.0% | 0.3% |
| Total Shareholder Yield | 2.7% | 3.6% | 1.2% | 0.2% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 2.0% | 0.3% |
| Shares Outstanding | — | $50M | $52M | $51M | $51M | $51M | $51M | $50M | $49M | $49M | $48M |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRL stock.
Charles River Laboratories International, Inc.'s current P/E ratio is -95.3x. The historical average is 27.9x.
Charles River Laboratories International, Inc.'s current EV/EBITDA is 17.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.3x.
Charles River Laboratories International, Inc.'s return on equity (ROE) is -4.3%. The historical average is 7.1%.
Based on historical data, Charles River Laboratories International, Inc. is trading at a P/E of -95.3x. Compare with industry peers and growth rates for a complete picture.
Charles River Laboratories International, Inc. has 30.5% gross margin and 12.6% operating margin. Operating margin between 10-20% is typical for established companies.
Charles River Laboratories International, Inc.'s Debt/EBITDA ratio is 3.4x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Goodwill impairment risk
Metrics are mathematically derived from official filings.
Margin Recovery Masks Underlying Strain
Gross margin expanded to 36.2% in 2026Q2 from 34.5% a year earlier, yet operating margin at 11.9% remains below the 14.8% peak in 2024Q2, indicating persistent cost pressures, per company filings.
The gross margin improvement suggests some cost pass-through or mix shift, but the operating margin's inability to recover to prior levels implies that the high-fixed-cost base is not generating operating leverage. The negative net margin of -0.1% in 2026Q2, despite positive operating income, points to recurring non-cash charges that obscure the underlying earning power. Investors should monitor whether the operating margin can sustain above 12% if revenue remains flat.
Return on Capital Stuck at Low Single Digits
ROIC has hovered between 0.9% and 1.8% over the past ten quarters, with 2026Q2 at 1.6%, reflecting a capital-intensive model where returns are insufficient to cover the cost of capital, based on reported figures.
The persistently low ROIC, despite a stable asset turnover of 0.13, indicates that the company's heavy investment in goodwill and fixed assets is not generating commensurate returns. The negative ROE in recent quarters, driven by impairments and buybacks, further erodes shareholder value. This suggests that the company is not compounding returns on invested capital, and any recovery would require either margin expansion or asset base rationalization.
Working Capital Cycle Lengthens Slightly
Cash conversion cycle extended to 95 days in 2026Q2 from 100 days a year earlier, with DSO stable at 64 days and DPO at 20 days, indicating limited improvement in working capital efficiency, as per quarterly data.
The modest reduction in CCC is driven by a slight decrease in DIO, but DPO remains low, suggesting the company is not leveraging supplier credit effectively. The stable DSO indicates that customer payment behavior is unchanged, but the overall cycle remains long, tying up cash in operations. This is particularly concerning given the negative revenue growth, as working capital efficiency could be a source of cash if managed more aggressively.
Leverage Creeps Higher as Equity Shrinks
Debt-to-equity rose to 1.06 in 2026Q2 from 0.83 in 2024Q1, while interest coverage fell to 2.75x from 4.65x, indicating a thinner cushion for debt service, according to balance sheet data.
The increase in leverage is partly due to a shrinking equity base from impairments and buybacks, rather than a significant rise in absolute debt. Interest coverage at 2.75x is still adequate but has deteriorated, and the negative interest coverage in 2025Q4 and 2026Q1 reflects the impact of non-cash charges on EBIT. With D/EBITDA at 16.18x, the company appears highly levered relative to current EBITDA, though this may be distorted by depressed earnings. Investors should monitor whether the company can generate sufficient cash flow to service debt without further asset sales or equity issuance.
Liquidity Adequate but Cash Buffer Thin
Current ratio improved to 1.35 in 2026Q2 from 1.29 in 2025Q4, but cash and equivalents remain low at $192M, providing a limited buffer against operational shocks, as reported in the balance sheet.
The current ratio suggests that short-term assets cover short-term liabilities, but the reliance on inventory and receivables, rather than cash, makes the position vulnerable to a sudden downturn. The quick ratio of 1.04 indicates that even without inventory, current assets nearly cover current liabilities, but the thin cash position means the company may need to rely on credit lines or asset sales in a stress scenario. Given the negative revenue growth and potential for further impairments, liquidity could become strained if cash generation falters.
EV/EBITDA Misleads on Leverage
EV/EBITDA of 16.91x appears reasonable, but with D/EBITDA at 16.18x, the multiple is distorted by depressed EBITDA, obscuring the true leverage burden, based on reported figures.
The EV/EBITDA multiple is commonly used for CRL, but it fails to capture the impact of non-cash charges that depress EBITDA, making the company appear cheaper than it is. A more appropriate metric would be EV/EBITDAR or EV/EBITDA adjusted for one-time items, which would provide a clearer picture of the company's operating performance. Additionally, investors should consider the high goodwill balance, which could lead to future impairments that further reduce equity and increase leverage ratios.